Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits

Veronika Altanerova, Dana Holicova, Lucia Kucerova, Cestmir Altaner, Michael Dale Lairmore, Kathleen Boris-Lawrie

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.

Original languageEnglish (US)
Pages (from-to)434-439
Number of pages6
JournalVirology
Volume329
Issue number2
DOIs
StatePublished - Nov 24 2004
Externally publishedYes

Fingerprint

Bovine Leukemia Virus
Virus Diseases
Rabbits
Infection
Genes
Retroviridae
Vaccination

Keywords

  • Live attenuated vaccine
  • Replication-competent retroviral vector
  • Rex-independent gene expression

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits. / Altanerova, Veronika; Holicova, Dana; Kucerova, Lucia; Altaner, Cestmir; Lairmore, Michael Dale; Boris-Lawrie, Kathleen.

In: Virology, Vol. 329, No. 2, 24.11.2004, p. 434-439.

Research output: Contribution to journalArticle

Altanerova, Veronika ; Holicova, Dana ; Kucerova, Lucia ; Altaner, Cestmir ; Lairmore, Michael Dale ; Boris-Lawrie, Kathleen. / Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits. In: Virology. 2004 ; Vol. 329, No. 2. pp. 434-439.
@article{c6f9ace72bf1418d9e29c9fd37e503cc,
title = "Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits",
abstract = "Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.",
keywords = "Live attenuated vaccine, Replication-competent retroviral vector, Rex-independent gene expression",
author = "Veronika Altanerova and Dana Holicova and Lucia Kucerova and Cestmir Altaner and Lairmore, {Michael Dale} and Kathleen Boris-Lawrie",
year = "2004",
month = "11",
day = "24",
doi = "10.1016/j.virol.2004.09.001",
language = "English (US)",
volume = "329",
pages = "434--439",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits

AU - Altanerova, Veronika

AU - Holicova, Dana

AU - Kucerova, Lucia

AU - Altaner, Cestmir

AU - Lairmore, Michael Dale

AU - Boris-Lawrie, Kathleen

PY - 2004/11/24

Y1 - 2004/11/24

N2 - Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.

AB - Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.

KW - Live attenuated vaccine

KW - Replication-competent retroviral vector

KW - Rex-independent gene expression

UR - http://www.scopus.com/inward/record.url?scp=7044260729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044260729&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2004.09.001

DO - 10.1016/j.virol.2004.09.001

M3 - Article

VL - 329

SP - 434

EP - 439

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -